Clinical Trial Update: Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of monthly recombinant Factor XIII (rFXIII) in paediatric subjects with congenital Factor XIII A-subunit defici…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Factor Xiii Deficiency

Drugs mentioned

• Recombinant Factor XIII (rFXIII) (Factor XIII, recombinant)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2016-06-24